- Optinose Inc (NASDAQ:OPTN) announced the statistically significant benefits of XHANCE in the ReOpen2 trial for the symptoms co-primary endpoint and the CT scan co-primary endpoint.
- Significant improvement was seen in patients with chronic sinusitis who did not have nasal polyps treated with both doses of XHANCE (fluticasone propionate) nasal spray compared to a vehicle Exhalation Delivery System (placebo).
- Related: Optinose's XHANCE Meets Primary Endpoints In Chronic Sinusitis Trial.
- The co-primary endpoints were a patient-reported composite symptom score measured at week 4 and an objective measure of disease in the sinus cavities at week 24.
- The safety profile and tolerability of XHANCE in this trial were generally consistent with its currently labeled safety profile.
- When pre-planned analyses are completed, detailed results from ReOpen2 will be submitted for publication in a peer-reviewed journal and presented at future medical meetings.
- Price Action: OPTN shares are up 34.60% at $2.49 during the market session on the last check Monday.
